Human CD4 þ T-cell epitopes were identified in interferon-beta (IFN-b)-1b. A prominent peptide epitope region was found that induced a proliferative response in 16% of all donors tested. Responses corresponded to the presence of the HLA-DR2 haplotype. Responsive donors expressing the HLA-DQ6 allele showed an increased level of proliferation to the epitope as compared to peptide-responsive HLA-DQ6 negative donors. A similar result was found for HLA-DR15-expressing donors. PBMC from donors expressing HLA-DR15 were more likely to proliferate in response to IFN-b in a whole-protein in vitro assay than donors who did not carry this haplotype. It is striking that the common DQ6 allele HLA-DQB1*0602 is found in linkage disequilibrium with HLA-DRB1*1501, and this combination defines the HLA genotype associated with the development of multiple sclerosis. The HLA association between a response to IFN-b and MS might explain the prevalence of neutralizing antibody development, and may underlie the etiology of the disease.
Introduction
Recombinant human interferon-beta (IFN-b) is an approved therapy for the chronic treatment of relapsing remitting multiple sclerosis (RRMS). IFN-b therapy is associated with an approximately 30% reduction in relapse rate. The mechanism of action of IFN-b in the treatment of RRMS is not clearly defined. Potential mechanisms include direct effects on regulatory T-cell survival, 1 changes in costimulatory molecule expression as affected by an upregulation of IL-10 expression, 2, 3 and the maintenance of the blood-brain barrier via interactions with matrix-metalloproteases. 4, 5 In a recent randomized, controlled, multicenter trial, which compared the efficacy and safety of IFN-b-1a 6 at two different doses, the higher dose was clearly more clinically effective, yet a 10 times higher proportion of patients (25 vs 2%) developed neutralizing antibodies (NAbs) when treated with the higher dose. Depending on the particular IFN-b therapy in place, which varies in the concentration of IFN-b administered and the route and frequency of injections, patients develop NAbs at a rate of about 5-30% typically within 24 months after initiating treatment. The current standard of care is to curtail IFN-b usage if antibodies to the therapy are present after 2 years of use. The presence of NAbs is associated with loss of bioavailable IFN-b. 7, 8 Anti- IFN-b antibodies are also associated with a loss of clinical efficacy. 9 The neutralizing antibody in multiple sclerosis (MS) patients is enriched for the IgG4 isotype, and neutralizing IgG antibodies as a whole are found at higher titers than in patients with the non-neutralizing antibody. 10 The development of IgG class antibodies has been shown to correlate with the development of an antigen-specific response by CD4 þ T cells. [11] [12] [13] [14] To investigate the basis for the development of NAbs, the sequence of human IFN-b-1b was examined for the presence of CD4 þ T-cell epitope regions using a previously established systematic in vitro method. 15 A set of 87 community donors was screened for proliferative responses to 15-mer peptides describing the entire sequence of IFN-b. A prominent response to one peptide was noted. The proliferative response to this peptide correlated with the presence of the HLA-DR2 haplotype (defined herein as HLA-DR15 þ /HLA-DQ6 þ ). Finally, an in vitro proliferative response to inactivated IFN-b-1b also correlated with the expression of HLA-DR15. This finding is potentially interesting in that the development of RRMS is also associated with the HLA-DR2 haplotype.
The identification of a prominent CD4 þ T-cell epitope in IFN-b and of critical residues for T-cell activation within the epitope should facilitate the development of second-generation IFN-b therapies with a reduced potential to induce NAbs in the specific disease-carrying population. A reduced immunogenicity IFN-b therapeutic would allow Nab-susceptible RRMS patients to extend their use of this beneficial treatment.
Results
Localization of a prominent CD4 þ T-cell epitope in human IFN-b Peripheral blood CD4 þ T-cells isolated from 87 community donors were tested for proliferation responsiveness to peptides derived from the sequence of human IFN-b-1b. Peptides were presented in vitro by autologous monocyte-derived dendritic cells in serum-free media. Each donor was tested with each peptide in duplicate. A stimulation index (SI) of 2.95 or greater was collated as a response to that peptide from that particular donor. The results for all 87 donors were compiled, and the percent of donors responsive to each peptide is shown in Figure  1a . The frequency of responses to peptides in the set is shown in Figure 1b . The average frequency of responses per peptide was found to be 2.79. The percent background response, 3.17%, was determined as the average percent responders over all the peptides in the set. The standard deviation was 3.28%. Poisson analysis of the data set reveals that the response rate for peptide #40 is significantly different (Po10 À6 ). Peptide #1 was also significant within this data set (P¼0.002). Peptide #1 represents amino acids 1-15 corresponding to the sequence MSYNLLGFLQRSSNF. Peptide #40 represents amino acids 118-132 corresponding to the sequence SSLHLKRYYGRILHY.
The average SI for each peptide over the entire data set of 87 community donors is shown in Figure 1c . On average, there was no response (SIB1) to any of the peptides in the data set, except for peptide #40. The average SI within the data set was 1.16, with a standard deviation of 0.21. Peptide #40 induced an average SI of 1.97, which is above the background, plus three standard deviations (1.79) for this data set. The prominent average SI for peptide #52 was a result of one donor contributing an SI of 28. The prominent average SI for peptide #1 was consistent over all responsive donors.
HLA associations for the two epitopes were determined. The peptide at position #1 showed no statistically significant HLA-DR or HLA-DQ associations. The peptide at position #40 displayed a strong association with HLA-DQ6 (Po0.02, relative risk¼2.76). An association with HLA-DR15 was also observed (Po0.05); however, the association to DQ6 was stronger than the association to DR15. The association to the DR15 allele could be due to linkage disequilibrium in the Caucasian ethnic group between DR15 and DQ6. This association became stronger with additional testing (see below).
Critical residue determination
The peptide #40 sequence was examined for the presence of amino-acid residues critical for the functional activation of human CD4 þ T cells. The peptide sequences at #1 and #40 were resynthesized, along with a set of alaninesubstituted peptides for each region. In addition, multiple alanine-substituted peptides were constructed that were based on published sequences, where the changes coincided with the discovered epitope regions, but did not significantly affect the activity of the mutated IFN-b molecule. 16 A set of 103 community donors was tested with the parent and modified epitope regions (Figure 2 ). This set of donors is independent of the original set of 87 donors tested with the IFN-b peptide set reported in Figure 1a . The overall response rate to peptide #1 was not reproduced with the resynthesized peptide (not shown). Therefore, for all donors tested (n¼190 donors in both tests), the frequency of responses at peptide #1 was no longer statistically significant over the background response rate and it was not examined further. A response rate of 16% was detected for peptide #40 in this new donor sets (Figure 2a) , which is consistent with the frequency of responses found in the original 87 donor set (see Figure 1a) . The same rate of responses was found for the resynthesized peptide #40 and for the original peptide when retested on this new donor set ( Figure 2a ). The HLA-DQ6 association with a response to peptide #40 was tested and reached a significance value of Po0.00005 (61.3% of responsive donors vs 24.7% in the nonresponder donors; relative risk 3.58). The HLA-DR15 association also remained highly significant, Po0.002. Applying a Bonferroni correction for multiple Figure 2b . Alanine replacements in the region from 125 to 129 were effective in reducing proliferation in both the 103-donor set and in the parent peptide responsive donors. In particular, the Y125A and I129A changes had a statistically significant effect on the average stimulation indices (Po0.001, paired, two-tailed Student's t-test).
HLA associations with increased proliferative responses to peptide #40 The average SIs from HLA-DQ6 þ and HLA-DQ6À donors within the responder (SI42.95) and the nonresponder groups were compared. Data from the peptide retest (n¼103 donors) were analyzed. As shown in Figure 3 , responding donors who carried the HLA-DQ6 allele had a statistically significant increase in the magnitude of their responses as compared to responding donors who did not carry the HLA-DQ6 allele (one-tailed Student's t-test, P¼0.04). Nonresponders to peptide #40 were not different regardless of their HLA-DQ6 status. Unfortunately, this data set did not contain a group of donors homozygous for HLA-DQ6.
The proliferative responses of all tested donors regardless of their peptide #40 responder status were averaged, and are presented in Figure 4 . The proliferative response to peptide 40 displayed by all donors, donors who expressed HLA-DQ6 at one or the other allele (n¼32), who expressed HLA-DR15 (n¼19), HLA-DR15 and HLA-DQ6 (n¼14) and the response by donors who expressed HLA-DR1 in the absence of HLA-DQ6 (n¼11) are shown. The magnitude of the averaged responses is significantly different (Po0.05, two-tailed nonparametric t-test) between the average for all donors (1.8870.15) and the donors who expressed HLA-DR15 (3.0370.38). In addition, the proliferative response by CD4 þ T cells from donors who expressed HLA-DR1 in the absence of HLA-DQ6 (n¼11; 1.1770.14) was significantly reduced with respect to the average response of all the donors (P¼0.002).
Taken together, these data suggest that the magnitude of the proliferative response induced to peptide #40 in human IFN-b is increased if the donor expresses either HLA-DR15 or HLA-DQ6. HLA-DQ6 þ responders to peptide 40 mount a high level of proliferation, while Y132A  H131A  I129A  R128A  G127A  Y126A  Y125A  R124A  K123A  L122A  H121A  L120A  S119A  S118A  #40  40parent   20  18  16  14  12  10  8  6  4 
HLA-DQ6 critical residue determination
As the presence of an HLA-DQ6 allele was associated with a more robust response to peptide #40 of human IFN-b, we excerpted the alanine scan data with respect to donors positive for HLA-DQ6. Of the total number of donors responsive to peptide #40 (n¼15), 10 donors expressed HLA-DQ6. The average SI for these 10 donors, as tested on the alanine scan peptides, is shown in Figure 5 . Alanine substitutions in the same region as defined on the whole population were also effective for reducing the response to this peptide in HLA-DQ6 þ individuals. The differences in proliferative values for the Y125A and I129A changes as compared to the parent peptide are both with Po0.0005, by a paired, two-tailed Student's t-test.
In vitro proliferative response of donor PBMC to heatinactivated IFN-b protein
To test if the HLA association noted for responses to the immunodominant peptide in human IFN-b would also be apparent if the intact protein molecule were used as an antigen, PBMC from a random sample of 20 community donors were cocultured for 6 days with 10 mg/ml of heat-inactivated commercial Betaseron (IFNb-1b, Berlex) . Proliferation was detected on day 6 using tritiated thymidine incorporation. The SI was calculated by dividing the average counts per minute in the Betaseron-containing wells by the average counts per minute in the control wells. The results are shown in Figure 6 . Of the nine donors who responded with SIs Y132A  H131A  I129A  R128A  G127A  Y126A  Y125A  R124A  K123A  L122A  H121A  L120A  S119A  S118A  #40 10.00 9.00 8.00 7.00 6.00 4.00 3.00 2.00 1.00 0.00
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Average stimulation index Figure 5 HLA-DQ6-bearing responsive donors to peptide #40. Anchor residues were determined by alanine scanning of peptide #40. The average SI for the 10 HLA-DQ6 þ responders to peptide #40 is shown. The differences at Y125A and I129A are different with a Po0.0005 by two-tailed, paired Student's t-test. Table 1 for complete donor information. 
Discussion
Human IFN-b was examined for the presence of human CD4 þ T-cell epitopes. A dendritic cell-based CD4 þ Tcell proliferation assay was used and data were collected for a large replicate of normal, community donors. A prominent epitope peptide was defined in the protein.
Response to the peptide, as defined by an SI of 2.95 or greater, was associated with the presence of HLA-DQ6 or HLA-DR15. The magnitude of the proliferative response positively associated with both alleles. Critical residue testing by performing iterations of the assay on alaninesubstituted peptides allowed the identification of critical residues in the epitope peptide sequence that controlled the proliferative response in vitro. Critical residues identified were similar in all responding donors and in the DQ6 þ responder subset. Finally, a proliferative response in vitro to heat-inactivated, whole-protein IFN-b was found to correspond to the presence of the HLA-DR15 allele in 20 community donors. The sequence of the identified peptide epitope determinant was compared to a nonredundant aminoacid sequence database using the BLAST algorithm. The sequence showed no homology to any protein other than IFN-b, suggesting that prominent crossreactive environmental proteins containing a homologous amino-acid sequence is not the cause of the accumulating positive responses in our assay. The positive responses are due to either endogenous autoimmune responses (see below) or are de novo antipeptide responses by naïve CD4 þ T cells occurring in vitro.
Human IFN-b contained only one immunodominant CD4 þ T-cell epitope when a total of 190 community donors were tested. The peptide region falls within the D-helix of the tertiary structure of the molecule. The Dhelix is not directly involved in receptor binding, and amino-acid substitutions have been made in this region without affecting the activity of the overall molecule. 16 We have identified amino acids within this peptide epitope as critical for the in vitro proliferative response. Multiple changes could be made in this region that could potentially reduce T-cell responses with minimal disruption to bioactivity.
The HLA-DR2 haplotype (DRB1*1501-DQB1*0602) has consistently been found to correlate with increased susceptibility to MS. [17] [18] [19] [20] [21] Interestingly, the DQ6 response to peptide #40 observed in our data was found to depend strongly on the DR antigen present in the same genotype. Specifically, we observed that 42% of responders to peptide #40 were DR15 þ and DQ6 þ , compared with 11% of nonresponders (Po1 Â 10
À5
; corrected for multiple comparisons Po2.1 Â 10 À4 , relative risk¼3.83). On the other hand, 19% of responders were DR13 þ DQ6 þ vs 13% of nonresponders (Po0.32, NS, relative risk¼1.5). This suggests that it is precisely the HLA class II DR and DQ combination associated with increased risk of MS that is associated with a proliferative response induced to peptide #40 in human IFN-b. Given that the DQ6 subtypes that accompany DR13 haplotypes (DQB1*0603, *0604, *0609) are different from those that occur on DR2 haplotypes (DQB1*0601 and *0602), it is not possible with the current data to distinguish between a DQ6 subtype vs a DR-induced effect in the proliferative response to IFN-b.
In addition to the positive association between the DR2 haplotype and a proliferative response to peptide #40, we found a negative association between the response to peptide #40 and the DR1 allele. The DR1 allele has been described as protective for the development of MS. 22 While these HLA associations with the development of MS and a proliferative response to peptide #40 in IFN-b are provocative, they are difficult to explain within the current understanding of the disease and may simply be coincidental. However, it is tempting to speculate that a proliferative response to IFN-b underlies the etiology of MS. Subclinical autoimmunity directed at endogenous IFN-b may predispose susceptible individuals to pathogenesis, perhaps by interfering with the proposed mechanisms of the action of exogenous IFN-b. With respect to this, it is interesting to note that a haplotype dose effect has been described for susceptibility for developing MS. 23, 24 The HLA-DR2 haplotype (HLA-DR15/DQ6) is very common in Caucasians. Our donor set of 186 HLA-type individuals expressed this haplotype at approximately 16%. The proportion of MS patients carrying one or two copies of the HLA-DR2 haplotype can be as high as 70%. 17 In the current set of donors, 43.3% of all DR15 þ DQ6 þ individuals displayed a proliferative response to peptide #40. Within a patient set similar to the one described by Barcellos et al, 17 it could be expected that at least 30% of the MS patients would develop a response to this peptide. Since a robust CD4 þ T-cell proliferative response is expected to be an obligatory prelude to the development of high titers of high-affinity IgG class antibodies, it could be extrapolated that these patients would be at risk to develop NAb to IFN-b.
All the data presented here were generated using community blood bank donor samples. The donors' disease status is unknown, but it can be presumed that MS patients would not be over-represented in the donor pool. A conclusive test of the presented hypothesis would require a longitudinal study of MS patients before and after IFN-b therapy to determine if HLA DR status correlates with the development of both neutralizing antibody and T-cell proliferative responses.
Materials and methods
Peptides Synthetic 15-mer peptides overlapping by 12 amino acids were purchased from Mimotopes (San Diego, CA, USA). Peptides were constructed using the Multi-Pin synthesis
technique. 25 The sequence for human IFN-b-1b ('Betaseron', Swissprot accession number P01574) containing the C17S mutation, and without the signal sequence, was used as a template for peptide synthesis.
Epitope variant peptides were also constructed using the Multi-Pin synthesis technique.
Human donors
Peripheral blood buffy coat samples were purchased from the Stanford University Blood Center, Palo Alto, CA, USA and BloodSource, Sacramento, CA, USA. All materials were handled in accordance with the Genencor International Bloodborne Pathogen Handling guidelines.
A total of 190 community donor samples were tested. HLA haplotyping data were collected for 186 of the donors.
HLA typing and analysis HLA-DRB1 and HLA-DQB1 alleles were determined for each donor using a commercially available kit (BioSynthesis, Lewisville, TX, USA). Low stringency results are reported. The presence of the HLA-DRB1*1501 allele is designated herein as 'HLA-DR15'. HLA-DQ6 designates all HLA-DQB1*06 alleles.
The distribution of DRB1 and DQB1 serological allele frequencies between IFN peptide responders and nonresponders was compared using a w 2 -test with one degree of freedom. The frequencies of 14 DR antigens and of seven DQ antigens were compared, resulting in a total of 21 nonindependent comparisons. Where noted, a Bonferroni correction for multiple comparisons has been applied based on 21 comparisons. Where an allele was present in both the responder and nonresponder populations, a relative risk value is reported.
Determination of CD4 þ T-cell epitopes CD4 þ T-cell peptide epitope determinants were identified using community donor blood as described. 15 Briefly, dendritic cells were differentiated in vitro from adherent monocytes. CD4 þ T cells from the autologous donor were cocultured with activated dendritic cells and peptide for 5 days in AIM V media (Life Technologies). Proliferation was assessed using tritiated thymidine incorporation. The CD4 þ T cell to dendritic cell ratio was 10:1. Peptides were included at B5 mM, in DMSO. DMSO was present at 0.25% volume. All positive and negative controls contained 0.25% DMSO. The positive control was tetanus toxoid (List Biologicals, Campbell, CA, USA). For each donor, peptides were tested in duplicate. Responses were averaged, and the average counts per minute (cpm) for each peptide was divided by the control cpm (DMSO only). An SI of 2.95 or greater was considered to be a positive response. The SI values were compiled for a large replicate of community donors. The percentage of donors responding to each peptide is reported.
In vitro PBMC proliferation PBMC from community donors were cultured at 2 Â 10 6 cells/ml in RPMI-1640 medium supplemented with 5% heat-inactivated human AB negative serum. Interferonb-1b (Betaseron) was resuspended according to the packaging insert to a concentration of 300 mg/ml. The material was heat inactivated by placing it at 1001C for 5 min. Inactivated IFN-b was added to the PBMC cultures at a final concentration of 10 mg/ml. Control cultures contained no IFN-b. Cultures were incubated at 371C for 5 days. On day 5, cultures were resuspended and 100 ml aliquots were transferred to 96-well plates. Tritiated thymidine was added at 0.5 mCi/well. Tritiated thymidine incorporation was assessed after 6 h. Each PBMC culture was tested in replicates of at least 10 wells. Significant responses were determined by comparing counts for the control and experimental wells. A parametric, two-tailed Student's t-test was performed. Significance was defined by Po0.05.
